Big Buttons

• FDA reconsiders on tirzepatide, big questions remain

  After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list. read more →

• Reporter briefing: Patient impacts of tirzepatide shortage resolution

  APC's media briefing shared compounders' first-hand stories with more than 30 reporters from across the country. read more →

• Be sure your marketing follows these best practices

  APC's new guide will help you stay on the right side of laws and regs. read more →

• A fake survey from a pharma-funded organization

  What the Partnership for Safe Medicines released "Ain't a legitimate survey." read more →

• Lots of letters

  On the compounding front, the FDA’s inbox is getting quite a workout lately. read more →

• Slick new dosing pen for compounders

  Love Lifesciences’ UniPen injector pen is not only a Very Big Deal, it's available at a discount for APC PFM members. read more →

• FDA says tirzepatide shortage “resolved”

  As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound. read more →

• Get yer law and patient safety CE here

  We've made the most popular segment of our 15-hour legal course into a standalone 3-hour, on-demand CE program. read more →

More News

San Diego’s KOGO has a short news piece on tirzepatide coming out of shortage, and its focus is on the price. It’s actually based on a CNN story, but we’re not quibbling — it quoted CEO Scott Brunner: “[T]he fact is, a lot of patients were able to afford the compounded versions of tirzepatide, and they’re likely not going to be able to afford the FDA-approved drug.”